{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T14:46:29Z","timestamp":1783781189784,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Acquired hemophilia A (AHA) is a rare disorder, and clinical practices for treating AHA have not been fully clarified in Japan.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>This study aims to investigate the epidemiology of AHA and real-world treatment practices in Japan.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients\/methods<\/jats:title>\n                <jats:p>This observational study was based on a health administrative database of hospitalized patients diagnosed with AHA who were treated with immunosuppressants.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study included 214 males and 124 females (mean age 75.7\u00a0years). The most frequently used bypassing agent was recombinant activated factor VII. The predominant choice of immunosuppressant for first-line treatment was steroid monotherapy. Median days from the index date to the start of rehabilitation was 65.0 for cardiovascular, 35.5 for respiratory and 23.0 for locomotor. The proportion of patients with an activities of daily living (ADL) score\u2009&lt;\u200970 points was high at both first admission and final discharge (47.4% and 38.8%). The percentage of deaths during hospitalization was 18.6%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study clarified the treatment patterns and clinical outcomes of AHA in a large population in Japan. This was the first study showing ADL score distribution and time to rehabilitation. Further investigation is needed to develop better clinical practices for treatment of AHA.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12185-022-03467-w","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T10:03:37Z","timestamp":1667556217000},"page":"44-55","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["ORIHIME study: real-world treatment patterns and clinical outcomes of 338 patients with acquired hemophilia A from a Japanese administrative database"],"prefix":"10.1007","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1459-3970","authenticated-orcid":false,"given":"Yoshiyuki","family":"Ogawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kagehiro","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Matsuo-Tezuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruko","family":"Yamaguchi-Suita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Nogami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,4]]},"reference":[{"key":"3467_CR1","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2491\/jjsth.19.140","volume":"19","author":"I Tanaka","year":"2008","unstructured":"Tanaka I, Amano K, Taki M, Oka T, Sakai M, Shirahata A, et al. A 3-year consecutive survey on current status of acquired inhibitors against coagulation factors in Japan\u2014analysis of prognostic factors. Jpn J Thromb Hemost. 2008;19:140\u201353.","journal-title":"Jpn J Thromb Hemost"},{"key":"3467_CR2","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1080\/10245330500276642","volume":"10","author":"M Franchini","year":"2005","unstructured":"Franchini M, Veneri D. Acquired coagulation inhibitor-associated bleeding disorders: an update. Hematology. 2005;10:443\u20139.","journal-title":"Hematology"},{"key":"3467_CR3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0950-3536(96)80067-9","volume":"9","author":"AJ Cohen","year":"1996","unstructured":"Cohen AJ, Kessler CM. Acquired inhibitors. Baillieres Clin Haematol. 1996;9:331\u201354.","journal-title":"Baillieres Clin Haematol"},{"key":"3467_CR4","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/j.1538-7836.2012.04654.x","volume":"10","author":"P Knoebl","year":"2012","unstructured":"Knoebl P, Marco P, Baudo F, Collins P, Huth-K\u00fchne A, Nemes L, et al. EACH2 Registry Contributors. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012;10:622\u201331.","journal-title":"J Thromb Haemost."},{"key":"3467_CR5","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1182\/blood-2015-09-672774","volume":"127","author":"A Tiede","year":"2016","unstructured":"Tiede A, Hofbauer CJ, Werwitzke S, Kn\u00f6bl P, Gottstein S, Scharf RE, et al. Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01\/2010 study. Blood. 2016;127:2289\u201397.","journal-title":"Blood"},{"key":"3467_CR6","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/hae.12138","volume":"19","author":"JY Borg","year":"2013","unstructured":"Borg JY, Guillet B, Le Cam-Duchez V, Goudemand J, L\u00e9vesque H. The SACHA Study Group. Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l\u2019H\u00e9mophilie Acquise) registry. Haemophilia. 2013;19:564\u201370.","journal-title":"Haemophilia."},{"key":"3467_CR7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1046\/j.1365-2141.2003.04731.x","volume":"124","author":"P Collins","year":"2004","unstructured":"Collins P, Macartney N, Davies R, Lees S, Giddings J, Majer R. A population based, unselected, consecutive cohort of patients with acquired haemophilia A. Br J Haematol. 2004;124:86\u201390.","journal-title":"Br J Haematol"},{"key":"3467_CR8","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1182\/blood-2006-06-029850","volume":"109","author":"PW Collins","year":"2007","unstructured":"Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, et al. UK Haemophilia Centre Doctors\u2019 Organisation. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors\u2019 Organisation. Blood. 2007;109:1870\u20137.","journal-title":"Blood."},{"key":"3467_CR9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/hae.13033","volume":"23","author":"K Amano","year":"2017","unstructured":"Amano K, Seita I, Higasa S, Sawada A, Kuwahara M, Shima M. Treatment of acute bleeding in acquired haemophilia A with recombinant activated factor VII: analysis of 10-year Japanese postmarketing surveillance data. Haemophilia. 2017;23:50\u20138.","journal-title":"Haemophilia"},{"key":"3467_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1046\/j.1365-2516.2002.00574.x","volume":"8","author":"RJ Moraca","year":"2002","unstructured":"Moraca RJ, Ragni MV. Acquired anti-FVIII inhibitors in children. Haemophilia. 2002;8:28\u201332.","journal-title":"Haemophilia"},{"key":"3467_CR11","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/pbc.22657","volume":"55","author":"M Franchini","year":"2010","unstructured":"Franchini M, Zaffanello M, Lippi G. Acquired hemophilia in pediatrics: a systematic review. Pediatr Blood Cancer. 2010;55:606\u201311.","journal-title":"Pediatr Blood Cancer"},{"key":"3467_CR12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s12185-017-2210-8","volume":"106","author":"Y Ogawa","year":"2017","unstructured":"Ogawa Y, Yanagisawa K, Uchiumi H, Ishizaki T, Mitsui T, Gouda F, et al. Clinical characteristics and outcomes of acquired hemophilia A: experience at a single center in Japan. Int J Hematol. 2017;106:82\u20139.","journal-title":"Int J Hematol"},{"issue":"28","key":"3467_CR13","first-page":"715","volume":"2017","author":"Committee of Clinical Practice Guid","year":"2017","unstructured":"Committee of Clinical Practice Guidelines for Acquired Hemophilia A. Guidelines for the management of acquired hemophilia A: 2017 revision. Jpn J Thromb Hemost. 2017;2017(28):715\u201347.","journal-title":"Jpn J Thromb Hemost."},{"key":"3467_CR14","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S0002-9343(98)00289-7","volume":"105","author":"P Bossi","year":"1998","unstructured":"Bossi P, Cabane J, Ninet J, Dhote R, Hanslik T, Chosidow O, et al. Acquired hemophilia due to factor VIII inhibitors in 34 patients. Am J Med. 1998;105:400\u20138.","journal-title":"Am J Med"},{"key":"3467_CR15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2491\/jjsth.27.64","volume":"27","author":"Y Seki","year":"2016","unstructured":"Seki Y, Miyakoshi S. A present state and clinical problems of long term outcome of patients with acquired hemophilia A in our hospital. Jpn J Thromb Hemost. 2016;27:64\u20139.","journal-title":"Jpn J Thromb Hemost"},{"key":"3467_CR16","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s12185-020-02823-y","volume":"111","author":"Ogawa Y,\u00b7Yanagisawa K, Naito C, Uch","year":"2020","unstructured":"Ogawa Y,\u00b7Yanagisawa K, Naito C, Uchiumi H, Ishizaki T, Shimizu H, et al. Overshoot of FVIII activity in patients with acquired hemophilia A who achieve complete remission. Int J Hematol. 2020;111:544\u20139.","journal-title":"Int J Hematol"},{"key":"3467_CR17","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.thromres.2015.10.032","volume":"136","author":"E Zanon","year":"2015","unstructured":"Zanon E, Milan M, Gamba G, Ambaglio C, Saggiorato G, Spiezia L, et al. Activated prothrombin complex concentrate (FEIBA\u00ae) for the treatment and prevention of bleeding in patients with acquired haemophilia: a sequential study. Thromb Res. 2015;136:1299\u2013302.","journal-title":"Thromb Res"},{"key":"3467_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/hae.14450","volume":"28","author":"VM Thomas","year":"2022","unstructured":"Thomas VM, Abou-Ismail MY, Lim MY. Off-label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: a scoping review of the literature. Haemophilia. 2022;28:4\u201317.","journal-title":"Haemophilia"},{"key":"3467_CR19","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1111\/jdi.12959","volume":"10","author":"Y Ikeda","year":"2019","unstructured":"Ikeda Y, Kubo T, Oda E, Abe M, Tokita S. Retrospective analysis of medical costs and resource utilization for severe hypoglycemic events in patients with type 2 diabetes in Japan. J Diabetes Investig. 2019;10:857\u201365.","journal-title":"J Diabetes Investig"},{"key":"3467_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2188\/jea.JE20200288","volume":"31","author":"K Hayashida","year":"2021","unstructured":"Hayashida K, Murakami G, Matsuda S, Fushimi K. History and profile of diagnosis procedure combination (DPC): development of a real data collection system for acute inpatient care in Japan. J Epidemiol. 2021;31:1\u201311.","journal-title":"J Epidemiol"},{"key":"3467_CR21","unstructured":"Medical Data Vision Corporation; [Internet].Tokyo. Overview of the medical administrative database (compiled at the end of May 2020): actual number of patients: 31.82 million. 2020. https:\/\/www.mdv.co.jp\/press\/2020\/detail_1328.html. Accessed 25 Oct 2021"},{"key":"3467_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/MD.0b013e31826b971f","volume":"91","author":"K Mazodier","year":"2012","unstructured":"Mazodier K, Arnaud L, Mathian A, Costedoat-Chalumeau N, Haroche J, Frances C, et al. Lupus anticoagulant-hypoprothrombinemia syndrome: report of 8 cases and review of the literature. Medicine (Baltimore). 2012;91:251\u201360.","journal-title":"Medicine (Baltimore)."},{"key":"3467_CR23","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1177\/0961203314558859","volume":"24","author":"SM Mulliez","year":"2015","unstructured":"Mulliez SM, De Keyser F, Verbist C, Vantilborgh A, Wijns W, Beukinga I, et al. Lupus anticoagulant-hypoprothrombinemia syndrome: report of two cases and review of the literature. Lupus. 2015;24:736\u201345.","journal-title":"Lupus"},{"key":"3467_CR24","first-page":"61","volume":"14","author":"FI Mahoney","year":"1965","unstructured":"Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J. 1965;14:61\u20135.","journal-title":"Md State Med J"},{"key":"3467_CR25","first-page":"81","volume":"42","author":"M Saito","year":"2015","unstructured":"Saito M, Hori K, Okamura D, Sakamoto J, Suzuki S, Nakazawa M, et al. Determinants of activities of daily living at discharge in elderly heart failure patients. Phys Therapy Jpn. 2015;42:81\u20139.","journal-title":"Phys Therapy Jpn"},{"key":"3467_CR26","unstructured":"Foundation for Promotion of Cancer Research, [Internet].Tokyo. Number of cancer incidence by age and site. 2018. https:\/\/ganjoho.jp\/public\/qa_links\/report\/statistics\/pdf\/cancer_statistics_2022_data_E.pdf. Accessed 6 June 2022"},{"key":"3467_CR27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2147\/JBM.S136060","volume":"8","author":"M Wang","year":"2017","unstructured":"Wang M, Cyhaniuk A, Cooper DL, Iyer NN. Identification of people with acquired hemophilia in a large electronic health record database. J Blood Med. 2017;8:89\u201397.","journal-title":"J Blood Med"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03467-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03467-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03467-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T14:10:56Z","timestamp":1672841456000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03467-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,4]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["3467"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03467-w","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,4]]},"assertion":[{"value":"22 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y. O, K. A. and K. N. received fees for their contribution to the development of this article or supplement from Chugai Pharmaceutical Co., Ltd. Outside of this article, K. A. received consultancy or advisory role and speakers bureau from Chugai Pharmaceutical Co., Ltd., and research funding and speakers Bureau for KM Biologics Co., Ltd., and speakers bureau for Bioverativ Inc., Bayer A\/G, Shire Plc, Takeda Pharmaceutical Co., Ltd., Sanofi S.A., Novo Nordisk A\/S, CSL Behring, and Pfizer Inc., and Japan Blood Products Organization. Y. M. T.<b>,<\/b> N. O.<b>,<\/b> Y. M., T. N., and H. Y. S. are current employees of Chugai Pharmaceutical Co., Ltd. K. N. received grants or contracts, payment or honoraria, speakers bureau for Takeda Pharmaceutical Co., Ltd., Sanofi S.A., CSL Behring, Chugai Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd., Bayer A\/G, Novo Nordisk A\/S, and KM Biologics Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}